DHEA is sold as a way to restore youth, energy, libido, and hormonal balance after menopause. The biology is more modest. DHEA is a hormone precursor, not a missing nutrient, and the evidence splits sharply between over-the-counter oral supplements and prescription vaginal treatment for genitourinary symptoms.
What DHEA is, and why menopause changes the conversation
Dehydroepiandrosterone, usually shortened to DHEA, is made mainly by the adrenal glands and circulates mostly as DHEA-S, its sulphated storage form. It can be converted in tissues into androgens and oestrogens, which is why it attracts so much attention in midlife medicine. The appeal is easy to understand: levels tend to fall with age, menopause changes sex-hormone biology, and many women are left with symptoms that medicine has historically under-studied or dismissed.
That does not make DHEA replacement straightforward. A lower DHEA-S number is not the same thing as a disease, and a hormone precursor does not behave like a simple top-up. Conversion depends on tissue, enzymes, dose, route, baseline health, and other hormones. The brain, skin, breast, liver, vagina, and hair follicles do not necessarily read the same DHEA signal in the same way.
This is where the menopause conversation often gets flattened. DHEA is discussed as if it were a general antidote to ageing. The better question is narrower: which form, for which symptom, in which group, with what monitoring, and over what time frame?
Oral DHEA has not lived up to the broad claims
The strongest caution comes from trials in postmenopausal women with normal adrenal function. A 2014 systematic review and meta-analysis in the Journal of Clinical Endocrinology & Metabolism, summarised in the NCBI Bookshelf, included 23 randomised trials and found that systemic DHEA was not associated with significant improvement in libido, sexual function, weight, glucose, lipids, or bone mineral density. The authors judged the evidence low confidence because many trials were small, imprecise, and at risk of bias.
That finding matters because most consumer claims for DHEA are broad. They imply better energy, better mood, better sex, better body composition, and slower ageing. Those claims ask the evidence to do more than it can. Some individual trials suggest possible signals in selected outcomes, but the overall picture is inconsistent, and short-term biomarker movement is not the same as a durable health benefit.
There is also a category error in much of the marketing. Menopause is not simply a DHEA deficiency state. Ovarian oestrogen production changes sharply, adrenal androgen production varies between women, and symptoms can come from sleep disruption, vasomotor symptoms, mood disorders, medicines, thyroid disease, iron deficiency, relationship stress, pain, and ordinary ageing. A capsule cannot diagnose that complexity.
Vaginal DHEA is a different question
The most defensible use of DHEA is not the anti-ageing supplement shelf. It is local vaginal treatment for genitourinary syndrome of menopause, the cluster of dryness, irritation, recurrent discomfort, urinary symptoms, and pain with sex that can follow low-oestrogen tissue changes. Here the route matters. Vaginal DHEA, also called prasterone, is used locally rather than as a general systemic supplement.
The North American Menopause Society’s 2020 position statement on genitourinary syndrome of menopause lists vaginal DHEA among options for moderate to severe symptoms, alongside low-dose vaginal oestrogen and ospemifene, when non-prescription measures are not enough. That is a much narrower claim than saying DHEA improves menopause. It is about a defined symptom cluster, a specific route, and a prescription product.
Even then, context matters. People with a history of breast cancer or other hormone-sensitive cancers need specialist guidance. The evidence base for local vaginal therapies in cancer survivors is more complicated than in the general postmenopausal population, and symptom burden has to be weighed against recurrence concerns, current endocrine therapy, and oncology input.
Testing a DHEA-S level is not a shortcut
A DHEA-S blood test can be useful in specific endocrine evaluations, especially when clinicians are investigating androgen excess. It is much less useful as a wellness score. A result in the lower part of the reference range does not prove that fatigue, low mood, low libido, or weight change is caused by DHEA.
The Endocrine Society’s clinical practice guideline on androgen therapy in women makes this point in a broader way. It recommends against diagnosing androgen deficiency syndrome in otherwise healthy women because there is no well-defined syndrome and symptoms do not correlate cleanly with measured androgen levels. It also recommends against the generalised use of DHEA in women because indications are inadequate and long-term safety data are lacking.
That is not a dismissal of symptoms. It is a warning against a simplistic test-and-replace model. Hormonal symptoms in midlife deserve careful assessment. They do not deserve a single-number explanation when the biology is more distributed than that.
The safety questions are not theoretical
DHEA is often sold beside vitamins, but it is not a vitamin. It is a hormone precursor with downstream androgenic and oestrogenic effects. Mayo Clinic’s current DHEA monograph warns that DHEA may raise androgen levels, can cause acne, oily skin, and unwanted male-pattern hair growth in women, may worsen mood disorders or raise mania risk, may lower HDL cholesterol, and should be avoided in pregnancy or breastfeeding. It also flags concern around hormone-sensitive cancers, including breast and prostate cancers.
The interaction list is equally important. Combining DHEA with oestrogen or testosterone may increase hormone-related side effects. Use with some antidepressants may raise concern about manic symptoms. People with bipolar disorder, hormone-sensitive cancer history, unexplained vaginal bleeding, liver disease, cardiovascular disease, high cholesterol, polycystic ovary syndrome, or complex medication schedules should not treat DHEA as a casual experiment.
Product quality adds another layer. Over-the-counter supplements are not regulated like prescription medicines. The dose on a label may not perfectly match the dose in the capsule, and contamination or inconsistent formulation is a recurring problem across the supplement market. For a hormone precursor, that uncertainty is not a small detail.
What this means in practice
- Treat oral DHEA as a hormone-active supplement with weak evidence for broad menopause, libido, body-composition, cognition, or anti-ageing claims.
- Separate prescription vaginal DHEA for genitourinary symptoms from oral DHEA capsules sold for general hormonal balance.
- Do not use a low-normal DHEA-S result as proof that DHEA is the cause of fatigue, low libido, low mood, or weight change.
- Seek medical advice before any DHEA discussion if there is a history of breast, ovarian, uterine, or prostate cancer, unexplained bleeding, bipolar disorder, liver disease, cardiovascular disease, high cholesterol, pregnancy, breastfeeding, or hormone therapy use.
- Be sceptical of products that promise youth, energy, fat loss, or hormone optimisation without naming the population, dose, route, trial evidence, and safety limits.
- If genitourinary symptoms after menopause are the problem, ask about the full range of evidence-based options rather than assuming an oral supplement is the relevant route.
What we don’t know
We do not know whether long-term oral DHEA use is safe for healthy postmenopausal women. We do not know whether small improvements in selected trial outcomes translate into better ageing, fewer fractures, better cardiometabolic outcomes, or sustained sexual wellbeing. We also do not know which women, if any, have a clinically meaningful symptom pattern that reliably predicts benefit from systemic DHEA.
The evidence is stronger for local vaginal DHEA than for broad oral supplementation, but even that evidence lives inside a defined indication. It should not be stretched into claims about cognition, muscle, metabolism, or longevity.
The most honest position is precise rather than enthusiastic. DHEA is biologically interesting and clinically relevant in some contexts. It is not a general menopause repair hormone, and it is not benign just because it is sold without a prescription.
Photo: National Cancer Institute on Unsplash.